The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonists may be beneficial when rapidly deployed in patients with severe COVID-19, as we discuss here.

中文翻译：

---

IL-6 是 COVID-19 治疗的关键细胞因子靶点吗？

在严重的 COVID-19 患者中发现 IL-6 水平升高，导致针对这种细胞因子的临床试验的快速发展。总体而言，这些试验不支持在轻度至中度疾病住院患者中广泛使用 IL-6 拮抗剂，但如我们在此讨论的，IL-6 拮抗剂在重症 COVID-19 患者中快速部署时可能有益。